The Blavatnik Fund for Innovation at Yale
Since 2017, Yale has awarded 55 Blavatnik Awards to 46 projects totaling $15 million* through the Blavatnik Fund for Innovation. The Fund is made possible by a generous grant from the Blavatnik Family Foundation in support of the commercialization of Yale faculty applied research and technology in the life sciences.
Alan Anticevic: Manifest Technologies
Angélique Bordey: Treating epilepsy in a genetically defined disorder, tuberous sclerosis complex
Jean-Ju Chung: The CatSper Male Contraceptive
John Deacon: Improving Small Molecule Therapy Through Targeted Drug Delivery to Solid Tumors
Anne Eichmann: Monoclonal Antibody mediated Blood-Brain Barrier opening
Mark Fields: Development of novel therapeutics for the treatment of age-related macular degeneration
Lynn Fiellin: Building a Data/Risk Analytics Dashboard to Identify At-Risk Teens Through Videogame Play
Jaime Grutzendler: Reversing Axonal Spheroids and Conduction Defects in Alzheimer’s Disease
Gloria Huang: De Novo Pyrimidine Synthesis Inhibition for the treatment of ARID1A mutated ovarian cancers and other solid tumors (morag to follow up) do not use combinations
Akiko Iwasaki: Pan-antiviral Antibodies
Smita Krishnaswamy: MoirAI: An Artificial Intelligence enabled Integrative Omics Drug Discovery Platform
Bruce Wexler: Next-Gen Treatment for CNS Disorders: Digital Neurotherapy from C8 Sciences
Qin Yan: Epigenetic immunotherapy
Choukri Ben Mamoun: Novel Therapy for Pantothenate Kinase-Associated Neurodegeneration
Demetrios Braddock: Targeting NETs in Human Disease
Joseph Contessa: Developing Therapeutic OST inhibitors
Anjelica Gonzalez: Aero Therapeutics, Inc
Mustafa Khokha: Small molecule regulation of β-catenin nuclear transport: new targets against cancer
Nikhil Malvankar: Faster, Reliable & Scalable DNA Sequencing using Biomolecular Electronics
Anna Pyle: Intron Therapeutics: Targeting the unique features of fungal metabolism to build a new generation of nontoxic drugs
Faye Rogers: Direct Targeting of Amplified Cancer Driver Genes as a Therapeutic Strategy
Kumar Ashtekar / Mark Lemmon: Drugging Fibrodysplasia Ossificans Progressiva
Jeffrey Bender: Target Site Blocker (TSB) of the IL-17A-miR466l-3p Interaction Prevents Progressive and Relapsing Remitting EAE
Choukri Ben Mamoun: EliV5: First-in-Class Antifungal Drugs
Ranjit Bindra: Athena Therapeutics - Targeting cancer at its core
Jonathan Bogan: Combatting obesity through a novel mechanism 2020
Sidi Chen: MAEGI Medicine - New Paradigm of Immune Gene Therapy
John Deacon: he Tumor Activated Permeability Platform: Targeting tumor acidity to enhance efficacy of known small molecule cancer therapeutics.
Barbara Ehrlich: NCS1-A New Target Enabled Therapeutic Approach for Wolfram Syndrome
Peter Glazer: Antibody-mediated gene editing
Ya Ha / Jonathan Ellman: Lkit Therapeutics: Exploiting synthetic lethality to target p53 mutant cancers
Akiko Iwasaki: CynAxis: Traversing the Blood Brain Barrier
Andrew Miranker: Breaking toxin propagation in multiple system atrophy
Sidi Chen: EvolveImmune: First in class cancer vaccines
John Deacon: Cytosolix: Improving small molecule therapy through targeted drug delivery to solid tumors
Naftali Kaminski: Sobetirome Clinical Trial for COVID-19 ARDS & Vittix Therapeutics: Curing Idiopathic Pulmonary Fibrosis with Thyroid Hormone Mimetics
Andrew Miranker: ADM THERAPEUTICS, LLC
Anna Pyle: Intronistat Therapeutics: Targeting the unique features of fungal metabolism for a new generation of nontoxic drugs
Aaron Ring: Breaking the Vicious Cycle of Inflammation and Cell Death in Sepsis
David Spiegel: MODA Pharmaceuticals
Paul Turner: Paci-PHI: Evolution-proof therapy against MDR bacterial pathogens
Jeffrey Bender: Target Site Blocker (TSB) of the IL-17A-miR466l-3p Interaction Prevents Progressive and Relapsing Remitting EAE
Anna Pyle / Akiko Iwasaki: Activating Immunity: RIG-I agonists as next-gen immunotherapies
Aaron Ring: Engineered IL-18 immunotherapy: An untapped cytokine pathway
Alanna Schepartz: Cell permeable miniature proteins
Paul Turner: Paci-PHI: Evolution-proof therapy against MDR bacterial pathogens
Anton Bennett: Targeting fibrosis by inhibition of phosphatases
Elliott Brown: A Novel Bone Marrow Aspiration Device
Andrew Miranker: TetraQ Therapeutics
Anna Pyle: Selective RNA vaccines for cancer
Mark Saltzman: StraDEFY Biodegradable Micro-Encapsulated Sunscreen
Alanna Schepartz: An Improved Strategy to Traffic Proteins into Cells
Stephen Strittmatter: Dual Fyn Pyk2 Kinase Inhibition for Alzheimer's Disease
Andrew Xiao: Rarebase Therapeutics